Saguaro Biosciences

Saguaro Biosciences, located in Quebec, Canada, focuses on developing non-toxic dyes for live-cell imaging, aimed at enhancing biological research in various scientific fields. Founded in 2020 in Quebec, Canada, Saguaro Biosciences specializes in non-toxic dyes for live-cell imaging. The company was co-founded by Brian D. , Felix Lavoie-Perusse, and Louis Turcotte, the latter of whom currently serves as CEO.

Saguaro has completed a total of 3 deals, with the most recent funding round occurring on June 4, 2024, when they raised USD 3. 000 mn in Seed funding from AQC Capital, Anges Québec, Investissement Quebec, and Ministère Économie, Science, Innovation du Québec. The total amount raised by the company stands at USD 3. 000 mn.

Saguaro Biosciences specializes in the development and commercialization of non-toxic dyes for live-cell imaging, focusing on enhancing biological insights in high-throughput screening environments. Their core product offerings include ChromaLIVE™, known for maintaining unaffected gene expression in cells, as well as NucleoLIVE™ and MortaLIVE™, which aid in live-dead assays and nuclear staining. These products enable researchers to visualize and analyze cellular responses in both 2D and 3D cultures while preserving cell physiology. Saguaro serves over 150 companies globally, targeting the biotechnology and pharmaceutical sectors, including prominent academic and research institutions across North America, Europe, and Asia.

Saguaro Biosciences generates revenue through direct sales of its proprietary live-cell dyes and drug profiling services. The company operates on a B2B model, where clients such as biotech and pharmaceutical firms procure products to enhance their research capabilities. Clients may utilize Saguaro’s reference dataset of over 3,000 annotated compounds for drug testing, placing orders for specific products like ChromaLIVE™, NucleoLIVE™, and MortaLIVE™. The company’s revenue model is bolstered by partnerships with research institutions, providing a comprehensive suite of imaging and data analysis services tailored to a diverse client base.

In June 2024, Saguaro Biosciences raised USD 3. 000 mn in Seed funding to support its platform development. The company plans to leverage this funding to enhance its product offerings and invest in new product development. Specific markets targeted for expansion include further penetration into the European and Asian biotech sectors.

Saguaro aims to introduce additional innovative products to meet the growing demands for live-cell imaging solutions, although specific launch dates for these products have not been disclosed.